HUP0301055A2 - Purinszármazékok - Google Patents
PurinszármazékokInfo
- Publication number
- HUP0301055A2 HUP0301055A2 HU0301055A HUP0301055A HUP0301055A2 HU P0301055 A2 HUP0301055 A2 HU P0301055A2 HU 0301055 A HU0301055 A HU 0301055A HU P0301055 A HUP0301055 A HU P0301055A HU P0301055 A2 HUP0301055 A2 HU P0301055A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- fluoroalkyl
- phenyl
- alkyl
- cycloalkyl
- Prior art date
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- -1 cyano- Chemical class 0.000 abstract 5
- 125000001624 naphthyl group Chemical group 0.000 abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000001589 carboacyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 abstract 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 abstract 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
A találmány az (I) általános képletű vegyületre, gyógyászatilagelfogadható sójára vagy szolvátjára vonatkozik, az (I) általánosképletben R1 jelentése hidrogénatom, alkil- vagy cikloalkilcsoport,amelyek mindegyike adott esetben egy vagy két helyettesítővelhelyettesített, amely helyettesítők hidroxil-, fluorenil-, fenil- vagynaftilcsoport, ahol a fenil- és a naftilcsoport adott esetbenhalogénatommal, alkil-, alkoxi- vagy cianocsoporttal helyettesített; Ajelentése kötés vagy alkiléncsoport; R2 jelentése i) hidrogénatom,alkil-, cikloalkil-, fenil vagy naftilcsoport, ahol a cikloalkil-,fenil- és naftilcsoport adott esetben alkil-, fenil-, alkoxi-(alkil)-, aminolkil-, fluoralkil-, fluoralkoxi-, alkanoil-, ciano-,cikloalkilcsoporttal, halogénatommal, -OR3, -COOR3, -S(O)mR4, -NR3R3,-SO2NR3R3, -CONR3R3, -NR3COR4 vagy -NR3SO2R4 általános képletűcsoporttal helyettesített, azzal a megkötéssel, hogy R2 jelentésehidrogénatomtól eltérő, amikor A jelentése kötés, vagy (ii) amikor Ajelentése alkilén- vagy cianocsoport vagy -NR3R3, -OR3, -COOR3, -OCOR4, -SO2R4, -SO2NR3R3, -NR3SO2R4, -NR3COR4 vagy -CONR3R3 általánosképletű csoport, vagy (iii) szénatomon keresztül kapcsolódó 4-11 tagúmono- vagy biciklusos heterociklus, amely 1-4 gyűrű nitrogénatomot,vagy 1 vagy 2 gyűrű nitrogénatomot és 1 gyűrű oxigén- vagy 1gyűrűkénatomot tartalmaz, adott esetben szénatomján oxo-, alkoxialkil-,aminoalkil-, fluoralkil-, fluoralkoxi-, fluoralkanoil-,cianocsoporttal, halogénatommal, -OR5, R6, -COR5, -NR5R5, -COOR5, -S(O)mR6, -SO2NR5R5, -CONR5R5, -NR5SO2R6 vagy -NR5COR6 általánosképletű csoporttal, továbbá nitrogénatomján adott esetbenalkoxialkil-, aminoalkil-, fluoralkil-, fluoralkanoil)-csoporttal, R6-COR5, -COOR6, -SO2R6, -SO2NR5R5 vagy -CONR5R5 általános képletűcsoporttal helyettesített, vagy iv) amikor A jelentése alkilén-,nitrogénatomon keresztül kapcsolódó azetidinil-, pirrolidinil-,morfolinil-, tetrahidroizokinolinil-, piperidinil- vagypiperazinilcsoport, ezek mindegyike adott esetben szénatomján alkil-,fenil-, alkoxialkil-, aminoalkil-, fluoralkil-, fluoralkoxi-,alkanoil-, ciano-, cikloalkilcsoporttal, halogénatommal, -OR3, -COOR3,-S(O)mR4, -NR3R3, -SO2NR3R3, -CONR3R3, -NR3COR4 vagy -NR3SO2R4általános képletű csoporttal helyettesített, továbbá apiperazinilcsoport adott esetben nitrogénatomján alkil-, fenil-,alkoxialkil-, aminoalkil-, fluor-alkil-, alkanoil-,cikloalkilcsoporttal, -COOR4, -SO2R4, -SO2NR3R3 vagy -CONR3R3általános képletű csoporttal helyettesített; R7 jelentésehidrogénatom, alkil-, cikloalkil-, fenil-, naftil-, azetidin-3-il-,pirrolidin-3-il-, piperidin-3-il-, piperidin-4-il-csoport vagyheterociklusos csoport, ahol az azetidin-3-il-, pirrolidin-3-il-,piperidin-3-il- és piperidin-4-il-csoport adott
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0003960.2A GB0003960D0 (en) | 2000-02-18 | 2000-02-18 | Purine derivatives |
PCT/IB2001/000167 WO2001060835A1 (en) | 2000-02-18 | 2001-02-09 | Purine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0301055A2 true HUP0301055A2 (hu) | 2003-08-28 |
Family
ID=9886026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0301055A HUP0301055A2 (hu) | 2000-02-18 | 2001-02-09 | Purinszármazékok |
Country Status (39)
Country | Link |
---|---|
US (1) | US6525032B2 (hu) |
EP (1) | EP1255764B8 (hu) |
JP (1) | JP2004508284A (hu) |
KR (1) | KR20030036138A (hu) |
CN (1) | CN1400975A (hu) |
AP (1) | AP2002002598A0 (hu) |
AR (1) | AR027437A1 (hu) |
AT (1) | ATE325807T1 (hu) |
AU (1) | AU2001230440A1 (hu) |
BG (1) | BG106906A (hu) |
BR (1) | BR0108408A (hu) |
CA (1) | CA2400619A1 (hu) |
CO (1) | CO5271668A1 (hu) |
CR (1) | CR6722A (hu) |
CZ (1) | CZ20022703A3 (hu) |
DE (1) | DE60119492T2 (hu) |
EA (1) | EA004987B1 (hu) |
EE (1) | EE200200452A (hu) |
ES (1) | ES2260199T3 (hu) |
GB (1) | GB0003960D0 (hu) |
GT (1) | GT200100027A (hu) |
HN (1) | HN2001000027A (hu) |
HR (1) | HRP20020676A2 (hu) |
HU (1) | HUP0301055A2 (hu) |
IL (1) | IL150543A0 (hu) |
IS (1) | IS6458A (hu) |
MA (1) | MA26873A1 (hu) |
MX (1) | MXPA02008068A (hu) |
NO (1) | NO20023894L (hu) |
NZ (1) | NZ519971A (hu) |
OA (1) | OA12177A (hu) |
PA (1) | PA8511801A1 (hu) |
PE (1) | PE20011122A1 (hu) |
PL (1) | PL357220A1 (hu) |
SK (1) | SK11692002A3 (hu) |
SV (1) | SV2002000317A (hu) |
TN (1) | TNSN01028A1 (hu) |
WO (1) | WO2001060835A1 (hu) |
ZA (1) | ZA200206526B (hu) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
GB9913932D0 (en) * | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
US6753322B2 (en) * | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
JP4514452B2 (ja) * | 2001-10-01 | 2010-07-28 | ユニバーシティ オブ バージニア パテント ファウンデーション | A2aアゴニスト活性を有する2−プロピルアデノシン・アナログおよびその組成物 |
GB0129273D0 (en) | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
GB0129270D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
GB0129397D0 (en) * | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE602005020286D1 (de) * | 2004-05-26 | 2010-05-12 | Inotek Pharmaceuticals Corp | Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür |
US7576069B2 (en) * | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
CN101068825B (zh) * | 2004-08-02 | 2013-05-08 | 弗吉尼亚大学专利基金会 | 具有a2a激动剂活性的具有修饰的5'-核糖基团的2-丙炔基腺苷类似物 |
US7442687B2 (en) * | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
AU2005286946B2 (en) * | 2004-09-20 | 2012-03-15 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
EP2532678A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
WO2007064795A2 (en) * | 2005-11-30 | 2007-06-07 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
US20080027022A1 (en) * | 2006-02-08 | 2008-01-31 | Linden Joel M | Method to treat gastric lesions |
WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
PT2013211E (pt) | 2006-04-21 | 2012-06-21 | Novartis Ag | Derivados de purina para utilização como agonistas de receptores a2a de adenosina |
GB0607951D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
JP2008285478A (ja) * | 2007-04-16 | 2008-11-27 | Santen Pharmaceut Co Ltd | アデノシンa2a受容体アゴニストを有効成分として含有する緑内障治療剤 |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
EA201200318A1 (ru) | 2009-08-20 | 2012-09-28 | Новартис Аг | Гетероциклические оксимы |
JP2013516495A (ja) | 2010-01-11 | 2013-05-13 | イノテック ファーマシューティカルズ コーポレイション | 眼圧を低下させる組合せ、キット、および方法 |
JP2013523739A (ja) | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
CA2828219A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
MX339302B (es) | 2011-09-15 | 2016-05-19 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. |
WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
BR112014018413A8 (pt) | 2012-01-26 | 2017-07-11 | Inotek Pharmaceuticals Corp | Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
CN105188714A (zh) | 2013-03-15 | 2015-12-23 | 伊诺泰克制药公司 | 眼用配制品 |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
EP3174545A1 (de) | 2014-07-28 | 2017-06-07 | Technische Universität Dresden | Effiziente hemmung von hsp27 |
RU2695230C2 (ru) | 2014-07-31 | 2019-07-22 | Новартис Аг | Сочетанная терапия |
TWI758146B (zh) * | 2015-03-13 | 2022-03-11 | 瑞典商杜比國際公司 | 解碼具有增強頻譜帶複製元資料在至少一填充元素中的音訊位元流 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5140015A (en) * | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
CA2347512C (en) * | 1998-10-16 | 2005-12-06 | Pfizer Inc. | Adenine derivatives |
GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
-
2000
- 2000-02-18 GB GBGB0003960.2A patent/GB0003960D0/en not_active Ceased
-
2001
- 2001-02-09 PL PL01357220A patent/PL357220A1/xx not_active Application Discontinuation
- 2001-02-09 DE DE60119492T patent/DE60119492T2/de not_active Expired - Fee Related
- 2001-02-09 JP JP2001560219A patent/JP2004508284A/ja active Pending
- 2001-02-09 CN CN01805069A patent/CN1400975A/zh active Pending
- 2001-02-09 NZ NZ519971A patent/NZ519971A/en unknown
- 2001-02-09 AU AU2001230440A patent/AU2001230440A1/en not_active Abandoned
- 2001-02-09 SK SK1169-2002A patent/SK11692002A3/sk unknown
- 2001-02-09 KR KR1020027010481A patent/KR20030036138A/ko active IP Right Grant
- 2001-02-09 EA EA200200770A patent/EA004987B1/ru not_active IP Right Cessation
- 2001-02-09 HU HU0301055A patent/HUP0301055A2/hu unknown
- 2001-02-09 MX MXPA02008068A patent/MXPA02008068A/es active IP Right Grant
- 2001-02-09 WO PCT/IB2001/000167 patent/WO2001060835A1/en active IP Right Grant
- 2001-02-09 ES ES01902583T patent/ES2260199T3/es not_active Expired - Lifetime
- 2001-02-09 AT AT01902583T patent/ATE325807T1/de not_active IP Right Cessation
- 2001-02-09 IL IL15054301A patent/IL150543A0/xx unknown
- 2001-02-09 EP EP01902583A patent/EP1255764B8/en not_active Expired - Lifetime
- 2001-02-09 BR BR0108408-9A patent/BR0108408A/pt not_active IP Right Cessation
- 2001-02-09 CA CA002400619A patent/CA2400619A1/en not_active Abandoned
- 2001-02-09 AP APAP/P/2002/002598A patent/AP2002002598A0/en unknown
- 2001-02-09 EE EEP200200452A patent/EE200200452A/xx unknown
- 2001-02-09 CZ CZ20022703A patent/CZ20022703A3/cs unknown
- 2001-02-09 OA OA1200200250A patent/OA12177A/en unknown
- 2001-02-12 GT GT200100027A patent/GT200100027A/es unknown
- 2001-02-15 PA PA20018511801A patent/PA8511801A1/es unknown
- 2001-02-15 HN HN2001000027A patent/HN2001000027A/es unknown
- 2001-02-15 AR ARP010100690A patent/AR027437A1/es not_active Application Discontinuation
- 2001-02-15 CO CO01012091A patent/CO5271668A1/es not_active Application Discontinuation
- 2001-02-16 SV SV2001000317A patent/SV2002000317A/es not_active Application Discontinuation
- 2001-02-16 PE PE2001000174A patent/PE20011122A1/es not_active Application Discontinuation
- 2001-02-16 TN TNTNSN01028A patent/TNSN01028A1/fr unknown
- 2001-02-20 US US09/789,236 patent/US6525032B2/en not_active Expired - Fee Related
-
2002
- 2002-07-05 BG BG106906A patent/BG106906A/xx unknown
- 2002-07-05 IS IS6458A patent/IS6458A/is unknown
- 2002-08-06 CR CR6722A patent/CR6722A/es not_active Application Discontinuation
- 2002-08-12 MA MA26771A patent/MA26873A1/fr unknown
- 2002-08-15 ZA ZA200206526A patent/ZA200206526B/en unknown
- 2002-08-16 NO NO20023894A patent/NO20023894L/no not_active Application Discontinuation
- 2002-08-19 HR HRP20020676 patent/HRP20020676A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0301055A2 (hu) | Purinszármazékok | |
CO5251399A1 (es) | Derivados de purina | |
NL300927I1 (nl) | tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat | |
MXPA04003795A (es) | Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos. | |
CO5261621A1 (es) | Derivados de purina | |
CA2126072A1 (en) | Tri-substituted phenyl derivatives and processes for their preparation | |
CO5280078A1 (es) | Compuestos | |
BR0307259A (pt) | Antibacterianos de fenil oxazolidinona substituìda bicìclica heterocìclica e composições e métodos relacionados | |
WO2004000817A3 (en) | Benzimidazole compounds and their use as estrogen agonists/antagonists | |
AR054857A1 (es) | Derivados de n- (heteroaril)-1- heteroarilquil-1 h - indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica | |
CY1106398T1 (el) | 6,7-διυδρο-5η-πυραζολο[1,2-α]πυραζολ-1-ονες οι οποιες ελεγχουν φλεγμονωδεις κυτοκινες | |
NO20052469L (no) | Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2. | |
NO20055333L (no) | Indazolderivater | |
ES8802518A1 (es) | Un procedimiento para preparar derivados de isoxazol y furano. | |
NO20015447L (no) | Kinolinderivater som inhibitorer av MEK enzymer | |
HRP20050628A2 (en) | Substituted benzoyl derivatives uses as herbicides | |
CO5320599A1 (es) | Inhibidores no peptidilicos de la union a las celulas depen dientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
NO20033145D0 (no) | Purinderivater som purinergiske reseptorantagonister | |
CY1105113T1 (el) | Παραγωγα της αρυλικης (ή ετepοαρυλικης) αζολυλκαρβυνολης για την αντιμετωπιση της ακρατειας ουρων | |
AR057668A1 (es) | Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparacion, composiciones farmaceuticas y su aplicacion en terapeutica | |
ATE497948T1 (de) | Bicyclische verbindungen | |
BG105417A (en) | Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance | |
IT1146726B (it) | Derivati della 2 ossoazetidina loro produzione ed impiego | |
NO944371L (no) | Kjemisk forbindelse med blodplateaggregeringsinhibiotoraktivitet | |
HUP0004142A2 (hu) | 5-HT1F agonista hatású karboxamidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |